CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC

The treatment of non-small cell lung cancer (NSCLC) has increasingly been driven by the presence of targetable driver mutations, including epidermal growth factor receptor (EGFR) mutations. Tyrosine receptor inhibitors (TKIs) have subsequently emerged as the standard-of-care treatment for EGFR-mutan...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Alexandria T M, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150033/
https://www.ncbi.nlm.nih.gov/pubmed/37138950
http://dx.doi.org/10.2147/LCTT.S408886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150033/
https://www.ncbi.nlm.nih.gov/pubmed/37138950
http://dx.doi.org/10.2147/LCTT.S408886

Ejemplares similares